Schonfeld Strategic Advisors LLC Pharvaris N.V. Transaction History

Schonfeld Strategic Advisors LLC

  • $13.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$15.2 - $28.05 $7,600 - $14,025
500 Added 4.2%
12,400 $347,000
Q3 2023

Nov 14, 2023
BUY
$14.68 - $21.4 $4,404 - $6,420
300 Added 2.59%
11,900 $248,000
Q2 2023

Aug 14, 2023
BUY
$7.82 - $16.0 $782 - $1,600
100 Added 0.87%
11,600 $175,000
Q1 2023

May 15, 2023
SELL
$6.34 - $12.27 $30,432 - $58,896
-4,800 Reduced 29.45%
11,500 $92,000
Q4 2022

Feb 14, 2023
BUY
$1.98 - $11.46 $32,274 - $186,798
16,300 New
16,300 $183,000

Others Institutions Holding PHVS

# of Institutions
51
Shares Held
39.6M
Call Options Held
0
Put Options Held
0
View Full List

About Pharvaris N.V.

PHVS Quotes by TradingView
  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $625M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email